In treating localized prostate cancer the efficacy of cryoablation is independent of DNA ploidy type.
While the prognostic value of DNA ploidy has been well established for radical prostatectomy, external beam radiation, brachytherapy and androgen deprivation therapy its role as a survival outcome predictor for prostate cancer patients treated with cryoablation has not yet been examined. Anecdotal evidence suggesting that cryoablation may be independent of DNA ploidy type led to the implementation of the current study. Retrospective analysis of data including flow digital cytometry was performed on 447 archival specimens taken from patients who had undergone cryosurgical ablation of primary prostate cancer. Five-year biochemical disease free survivals (bDFS) (defined as PSA thresholds of 0.5 and 1.0 ng/ml) were determined with Kaplan-Meier analysis. Patients were grouped according to DNA ploidy types then stratified by Gleason grade, risk group, pre-surgical PSA level, and disease stage. Mean and median age of the cohort was 65 and 64.6 years. Mean follow-up was 65.7 months. The DNA ploidy status of the population was found to be 59% diploid, 13% tetraploid, and 28% aneuploid. Using PSA < 1.0 ng/ml criterion, the bDFS rates for diploid, tetraploid, and aneuploid were 78%, 75%, and 79% respectively. The bDFS rates using a PSA < 0.5 ng/ml criterion were 67%, 59%, and 69% for diploid, tetraploid, and aneuploid groups. No significant outcome differences were found in stratified analysis. This investigation demonstrates that the efficacy of cryoablation is independent of DNA ploidy type.
Bahn
Duke K
DK
Prostate Institute, Community Memorial Hospital, 168 N. Brent, Suite 402, Ventura, CA 93003, USA. dbahn@cmhhospital.org
Silverman
Paul
P
Lee
Fred
F
Badalament
Robert
R
Bahn
Eric D
ED
Rewcastle
John C
JC
D000368:Aged; D000782:Aneuploidy; D003452:Cryosurgery; D004273:DNA, Neoplasm / Q000235:genetics*; D004171:Diploidy; D018572:Disease-Free Survival; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011003:Ploidies; D011123:Polyploidy; D011471:Prostatic Neoplasms / Q000235:genetics / Q000401:mortality / Q000601:surgery*; D016896:Treatment Outcome
D004273:DNA, Neoplasm